Facial Aesthetic Analysis Model Based on Clinical Cohort Phenotype to Explore 45° Facial Profile.
Launched by LINYU XU · May 14, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
In the analysis of facial aesthetics, the 45° profile has a unique advantage in evaluating lip protrusion, zygomatic fullness, and contour curve. Compared to the frontal view, this angle provides a more three-dimensional and deeper perspective. In a previous study, the research group found that the shape of the midface area at 45° influences the evaluation of lip protrusion. In this study, a digital model was used to simulate the protrusion of different midface areas in order to explore the differences in facial fixation patterns and aesthetic evaluations among various individuals at 45°. B...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Orthodontist inclusion criteria: ① With dental doctor qualification certificate; ② At least 2 years of professional training in orthodontics.
- • Inclusion criteria for orthodontic patients: ① Receiving orthodontic treatment for more than 1 year; ② Volunteer to participate in the study; ③ Native language is Chinese, can understand the prompt language and normal communication.
- • General adult inclusion criteria: ① have not experienced orthodontic treatment or have no need for orthodontic treatment; ② Do not engage in stomatology industry, have not studied stomatology specialty; ③ Native language is Chinese, can understand the prompt language and normal communication.
- Exclusion Criteria:
- • ① have visual impairment (such as color blindness, high myopia); ②Have psychological problems (such as autism, schizophrenia); ③ Recent use of alcohol, or long-term fatigue, anxiety; Current use of any medication that may affect cognitive ability; ⑤ Use mascara, contact lenses or small frame height glasses
About Linyu Xu
Linyu Xu is a dedicated clinical trial sponsor focused on advancing medical research through innovative study designs and robust scientific methodologies. With a commitment to enhancing patient outcomes and safety, Linyu Xu collaborates with leading healthcare professionals and institutions to facilitate the development of groundbreaking therapies. Their expertise spans multiple therapeutic areas, ensuring a comprehensive approach to clinical trials that prioritizes transparency, compliance, and ethical standards. By leveraging cutting-edge technologies and data-driven insights, Linyu Xu aims to contribute significantly to the evolution of healthcare and the betterment of patient lives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, Fujian, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported